Program enables in-center dialysis patients to travel to
Universal EXPO in Milan and access
therapy with flexible System One; Expands Milan travel options for
NxStage patients
LAWRENCE, Massachusetts,
Sept. 11, 2015 /PRNewswire/
-- NxStage Medical, Inc. (Nasdaq: NXTM), a leading
manufacturer of dialysis products and Spindial S.p.A., a
distributor of renal care products in Italy, announced today their new partnership
with the Niguarda-Ca' Granda hospital in Milan, Italy to help assist hemodialysis
patients, including both current NxStage patients and non-NxStage
patients, who wish to travel to Milan. Through this partnership and under the
guidance and prescription of their physicians and the support and
coordination of their treating dialysis clinics, in-center
hemodialysis patients may have the opportunity to travel to
Milan and access therapy using the
NxStage System One at the Milan
hospital. The hospital's experienced staff will
administer treatments to these dialysis patients consistent with
their prescription using the System One. In addition, while
the portability of the System One enables NxStage patients to
perform their treatments while traveling, this partnership may
provide them the additional options of performing their treatments
at their travel destination in Milan with a System One provided by the
hospital, or at the hospital under the guidance of their trained
staff.
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
Logo - http://photos.prnewswire.com/prnh/20150624/225341
Patients can have the amazing opportunity to more easily
discover the famous architecture of Milan or visit the Universal EXPO, being held
until October 31, 2015. NxStage,
Spindial, and Niguarda-Ca' Granda look forward to welcoming
patients in Italy.
For further information on on this program, please contact local
customer care service:
-In Italy: cristina.baroni@spindial.it , +39 (0) 346 373
3232
-In North America: customerservice@nxstage.com , +1-866-NXSTAGE
(+1-866-697-8243)
-In United Kingdom: customerservice@nxstage.com , +44 (0) 800 048
8352
-In other countries: contact a local distributor:
http://www.nxstage.com/ourcompany/global-partners.
The NxStage System One is a prescription device. All forms of
hemodialysis, including treatments performed in-center, in-hospital
and at home, involve some risks. In addition, there are certain
risks unique to treatment in the home environment. Patients should
talk to their doctor and dialysis clinic to understand if they are
healthy enough to travel internationally and whether this program
is medically appropriate for them.
The risks associated with hemodialysis treatments in any
environment include, but are not limited to, high blood pressure,
fluid overload, low blood pressure, heart-related issues, and
vascular access complications. The medical devices used in
hemodialysis therapies may add additional risks including air
entering the bloodstream and blood loss due to clotting or
accidental disconnection of the blood tubing set. Certain risks are
unique to the home. Treatments at home are done without the
presence of medical personnel and on-site technical support.
Patients and their partners must be trained on what to do and how
to get medical or technical help if needed.
Travel requirements are unique depending upon the
jurisdiction a patient may travel from and to. Patients
should speak with their physician and treating dialysis clinic to
understand what requirements they may need to satisfy in order to
travel to Milan, Italy and receive
treatment there. Patients should also speak with appropriate
regulatory authorities to further understand these
requirements.
About the NxStage System One
The NxStage System One is the first and only truly portable
hemodialysis system cleared specifically by the FDA for home
hemodialysis and home nocturnal hemodialysis. Its simplicity and
revolutionary size (just over a foot tall) are intended to allow
convenient use in patients' homes and give patients the freedom to
travel with their therapy. When combined with the NxStage PureFlow
SL Dialysis Preparation System, patients are able to further
simplify, using ordinary tap water to create dialysis fluid on
demand. Unlike conventional hemodialysis systems, the System One
requires no special infrastructure to operate. Under the guidance
of their physician, patients can use the NxStage System One, with
their trained partners, where, how and when it best meets their
needs, including while they are sleeping - at home or on vacation
and at a medically appropriate treatment frequency.
http://www.nxstage.com/.
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company,
headquartered in Lawrence,
Massachusetts, USA, that develops, manufactures and markets
innovative products for the treatment of ESRD and acute kidney
failure. For more information on NxStage and its products, please
visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including the Quarterly Report on Form 10-Q for the quarter ended
June 30, 2015. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: +1-978-332-5923